针对与阿尔茨海默氏病有关的躁动患者Ono-2020的研究
一项2A期,多中心,安慰剂对照,随机,双盲,平行组研究,以评估Ono-2020对与阿尔茨海默氏病有关的躁动患者的疗效和安全性
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:North America Clinical Trial Support Desk
- 电话号码:+18665877745(Toll-Free)
- 邮箱:clinical_trial@ono-pharma.com
研究联系人备份
- 姓名:International Clinical Trial Support Desk
- 电话号码:+17162141777(Standard)
- 邮箱:clinical_trial@ono-pharma.com
学习地点
-
-
-
Aichi、日本
- 招聘中
- Hotei Hospital
-
Akita、日本
- 招聘中
- Akita Prefectural Center For Rehabilitation and Psychiatric Medicine
-
Akita、日本
- 招聘中
- Medical Corporation Keishinkai Kyowa Hospital
-
Aomori、日本
- 招聘中
- Aiseikai General Incorporated Foundation, Hirosaki Aiseikai Hospital
-
Aomori、日本
- 招聘中
- Seinan Hospital
-
Fukui、日本
- 招聘中
- Fukui Hospital
-
Fukui、日本
- 招聘中
- Matsubara Hospital
-
Fukuoka、日本
- 招聘中
- Kuramitsu Hospital
-
Fukuoka、日本
- 招聘中
- Aburayama Hospital
-
Gunma、日本
- 招聘中
- Kishikai Kishi Hospital
-
Hiroshima、日本
- 招聘中
- Hayakawa Clinic
-
Hiroshima、日本
- 招聘中
- Koseikai Cocoro Hospital Kusatsu
-
Hiroshima、日本
- 招聘中
- Nakamura Hospital
-
Hokkaido、日本
- 招聘中
- Keiseikai Hospital
-
Hokkaido、日本
- 招聘中
- NHO Obihiro National Hospital
-
Kagoshima、日本
- 招聘中
- Ishiki Hospital
-
Kagoshima、日本
- 招聘中
- Airanomori Hospital
-
Kagoshima、日本
- 招聘中
- Sansyu Hospital
-
Kagoshima、日本
- 招聘中
- Taniyama Hospital
-
Kanagawa、日本
- 招聘中
- Hatano Kousei Hospital
-
Kanagawa、日本
- 招聘中
- Fujisawahospital
-
Kanagawa、日本
- 招聘中
- Showa Medical University Northern Yokohama Hospital
-
Kochi、日本
- 招聘中
- Hosogi Hospital
-
Kochi、日本
- 终止
- Ichiyo Mental Hospital
-
Kyoto、日本
- 招聘中
- Maizuru Medical Center
-
Kyoto、日本
- 招聘中
- Nishiyama Hospital
-
Miyagi、日本
- 招聘中
- Iryohojin Shadan Shoshinkai Morinohosupitaru・Aoba
-
Nagano、日本
- 招聘中
- JA-Nagano North Alps Medical Center Azumi Hospital
-
Nagano、日本
- 招聘中
- Jizenkai Ando Hospital
-
Nara、日本
- 招聘中
- Nara Medical University Hospital
-
Osaka、日本
- 招聘中
- Nagaokai Neyagawa Sanatorium
-
Osaka、日本
- 招聘中
- Osaka Institute of Clinical Psychiatry Shin-Abuyama Hospital
-
Osaka、日本
- 招聘中
- Osaka Psychiatric Medical Center
-
Saga、日本
- 招聘中
- Hizen Psychiatric Center
-
Saga、日本
- 招聘中
- Rainbow & Sea Hospital
-
Saitama、日本
- 招聘中
- Saitama Konan Hospital
-
Tokyo、日本
- 终止
- Asuka Hospital
-
Tokyo、日本
- 终止
- Nishigahara Hospital
-
Yamagata、日本
- 招聘中
- Sanyokai Sanyo Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of probable AD according to the diagnostic criteria for AD dementia (NIA-AA 2011)
- Mini-Mental State Examination (MMSE) score ≥ 5 to ≤ 22 at the start of the treatment period
- Symptoms of agitation defined by the IPA from at least 14 days before the start of the screening period
- Neuropsychiatric Inventory-Nursing Home version (NPI-NH) Agitation/Aggression domain (NPI-NH-A/A) score ≥ 4 at the start of the treatment period.
- Patients who can participate in the study under hospitalization from 21 days before the start of the treatment period to throughout the treatment period
Exclusion Criteria:
- Diagnosis of dementia not due to AD or any other disorder with memory impairment, such as mixed dementia, vascular dementia, Lewy body dementia, dementia associated with Parkinson's disease, frontotemporal dementia, drug-induced dementia, dementia associated with human immunodeficiency virus (HIV) infection, traumatic brain injury, normal pressure hydrocephalus, or other non-AD dementia
- Any MRI or CT scan of the brain performed after the onset of dementia with findings consistent with clinically relevant CNS disease other than AD, such as vascular changes (eg, cortical cerebral infarction, multiple cerebral infarctions), space-occupying lesions (eg, tumors), or any other major structural brain disease
- Delirium within 30 days before the start of the screening period or a history of delirium
- At risk of suicide according to the Columbia-Suicide Severity Rating Scale (C-SSRS) (answers "yes" to Question 4 or 5 of the suicidal ideation section of the C-SSRS) or any suicide attempt within 6 months before the start of the screening period, or at serious risk of suicide in the opinion of the investigator or subinvestigator
- Prior or current treatment with anti-amyloid beta antibodies
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Two ONO-2020 placebo tablets will be orally administered once daily |
|
实验性的:Ono-2020
|
ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in CMAI score from baseline
大体时间:up to week 12
|
To assess agitation symptoms |
up to week 12
|
|
Adverse events
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Body weight
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Body temperature
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Blood pressure
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Pulse rate
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
Respiratory rate
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
|
ECG RR interval
大体时间:up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG PR interval
大体时间:up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QRS complex
大体时间:up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QT interval
大体时间:up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
ECG QTcF
大体时间:up to week 12
|
To Evaluate the Safety |
up to week 12
|
|
Number of participants with abnormal laboratory tests (hematology)
大体时间:up to week 12
|
Hematology (PT, RBC count, RBC indices, WBC count, Differential, Hemoglobin, Hematocrit) |
up to week 12
|
|
Number of participants with abnormal laboratory tests (Clinical chemistry)
大体时间:up to week 12
|
Clinical chemistry (Blood urea nitrogen (BUN), Potassium, Creatinine, Sodium, Glucose (fasting or nonfasting), Calcium, Chloride, Total protein, Albumin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase, Total and direct bilirubin, Lactate dehydrogenase (LDH), Phospholipid, γ-Glutamyl transferase (GGT) |
up to week 12
|
|
Number of participants with abnormal Blood coagulation profile (Activated partial thromboplastin time (APTT), Prothrombin time (PT), International normalized ratio (INR))
大体时间:up to week 12
|
Blood coagulation (Activated partial thromboplastin time (APTT), Prothrombin time (PT), International normalized ratio (INR)) |
up to week 12
|
|
Number of participants with abnormal Urinalysis
大体时间:up to week 12
|
Urinalysis (pH, Glucose, Protein, Blood, Ketones) |
up to week 12
|
|
COLUMBIA-SUICIDE SEVERITY RATING SCALE(C-SSRS)
大体时间:up to week 16
|
To Evaluate the Safety |
up to week 16
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cohen-Mansfield Agitation Inventory (CMAI) score at each visit and change from baseline
大体时间:up to 12 week
|
To Evaluate the Efficacy The range of CMAI score is 29-203. Higher score means a worse outcome. |
up to 12 week
|
|
Clinical Global Impression-Severity (CGI-S) score at each visit and change from baseline
大体时间:up to 12 week
|
To Evaluate the Efficacy The range of CGI-S score is 0-7. Higher score means a worse outcome. |
up to 12 week
|
|
Clinical Global Impression-Severity (CGI-S) score at each visit
大体时间:up to 12 week
|
To Evaluate the Efficacy |
up to 12 week
|
|
Neuropsychiatric Inventory in Nursing Home Version(NPI-NH) score at each visit and change from baseline
大体时间:up to 12 week
|
To Evaluate the Efficacy The range of NPI-NH score is 0-170. Higher score means a worse outcome. |
up to 12 week
|
|
Mini Mental State Exam(MMSE) score at baseline and Week 12, and change from baseline
大体时间:up to 12 week
|
To Evaluate the Efficacy The range of MMSE score is 0-30. Higher score means a better outcome. |
up to 12 week
|
|
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)score at baseline and Week 12, and change from baseline
大体时间:up to 12 week
|
To Evaluate the Efficacy The range of ADCS-ADL score is 0-78. Higher score means a better outcome. |
up to 12 week
|
|
Duration of the investigational medicinal product administration
大体时间:up to 12 week
|
To Evaluate the Efficacy |
up to 12 week
|
|
Pharmacokinetic assessments
大体时间:up to 12 week
|
Plasma ONO-2020 concentrations |
up to 12 week
|
合作者和调查者
调查人员
- 研究主任:Project Leader、Ono Pharmaceutical Co., Ltd.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ONO-2020-03
- jRCT2041230153 (注册表标识符:Japan Registry of Clinical Trials)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.